- In March 2026, Indivior Pharmaceuticals announced a new cost impact model showing that its monthly extended-release buprenorphine injection SUBLOCADE® may significantly reduce staff time and related costs for treating opioid use disorder in jails and prisons compared with other medications.
- The study highlights that eliminating daily observed dosing and patient escorts could yield meaningful operational efficiencies for correctional facilities, although the model does not include drug acquisition costs and relies on several assumptions.
- We’ll now examine how the potential correctional staffing and cost efficiencies from SUBLOCADE® might influence Indivior’s broader investment narrative.
Find 63 companies with promising cash flow potential yet trading below their fair value.
Indivior Pharmaceuticals Investment Narrative Recap
To own Indivior, you need to believe long acting injectable treatments for opioid use disorder can keep expanding and support healthy profitability, even as the company manages a concentrated product portfolio and new U.S. listing structure. The new SUBLOCADE® cost impact model in correctional settings is interesting, but it does not yet appear to change the most important near term catalyst of execution on SUBLOCADE growth or the key risk around dependence on a single core asset.
Among recent announcements, the US$400 million share repurchase program stands out alongside strong 2025 results, with net income reaching US$210 million and revenue US$1,239 million. Together, these point to management’s confidence in the business and reinforce how SUBLOCADE performance and cost control could drive operating leverage, while also highlighting the ongoing risk that concentration in a focused OUD portfolio leaves Indivior exposed if market access or category adoption disappoints.
However, investors should also weigh how Indivior’s reliance on access and reimbursement in a handful of core markets could become a problem if...
Read the full narrative on Indivior Pharmaceuticals (it's free!)
Indivior Pharmaceuticals’ narrative projects $1.2 billion revenue and $477.5 million earnings by 2028. This requires 1.7% yearly revenue growth and a roughly $353 million earnings increase from $124.0 million today.
Uncover how Indivior Pharmaceuticals' forecasts yield a $37.86 fair value, a 24% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already assuming revenue of about US$1.3 billion and earnings near US$596 million by 2029, so this new correctional cost model could either support their bullish view on SUBLOCADE penetration or prompt a rethink, depending on how you see the risk that policy or reimbursement shifts in core markets might restrict access and slow that upside.
Explore 4 other fair value estimates on Indivior Pharmaceuticals - why the stock might be worth just $32.35!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Indivior Pharmaceuticals research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Indivior Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Indivior Pharmaceuticals' overall financial health at a glance.
No Opportunity In Indivior Pharmaceuticals?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.
- Invest in the nuclear renaissance through our list of 94 elite nuclear energy infrastructure plays powering the global AI revolution.
- Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com